Preston S. Gable

MD

Department of Primary Appointment:
School of Medicine
Medicine
Location: Naval Medical Center, San Diego, CA
Research Interests:
Hematology/Oncology
Oncology clinical research
Office Phone

Education

1981-1985 University of Minnesota, College of Biological Sciences Minneapolis, MN Bachelor of Science summa cum laude, Biochemistry
1985-1989 University of Minnesota, School of Medicine Minneapolis, MN Doctor of Medicine
1989-1992 Residency: Internal Medicine, Naval Medical Center, San Diego, CA
1992-1995 Fellowship: Hematology/Oncology, Naval Medical Center, San Diego, CA

Biography

Preston Gable MD, FACP (CAPT, MC, USN/RET) is a native of Minneapolis, Minnesota. He earned a Bachelor of Science degree Summa cum Laude in Biochemistry from the University Of Minnesota College Of Biological Sciences. He then attended the University Of Minnesota School Of Medicine, earning a Doctor of Medicine degree, and membership in the Alpha Omega Alpha Medical Honor Society. He did his internship and residency in internal medicine as well as his fellowship in hematology and oncology at the Naval Medical Center, San Diego from 1989-1995, and then joined on there as a staff physician in the division of Hematology/Oncology. He was advanced to fellowship in the American College of Physicians in 1998. He served as head of the Hematology/Oncology Department from 2001-2012 when he retired from active duty and was rehired to stay on as a civilian physician. He was awarded “Master Teacher of the Year” in 2013 by the Navy Chapter of the American College of Physicians, and is a Master Clinician at the Naval Medical Center, San Diego. He is an Assistant Professor at UCSD and USUHS, and an associate member of the John P. Murtha Cancer Center.

Career Highlights: Positions, Projects, Deployements, Awards and Additional Publications

1989-2012 United States Navy US Navy Retired as Captain September 2012.

1995-2001 Staff Physician, Division of Hematology/Oncology, Naval Medical Center, San Diego

2001-2012 Chairman, Department of Hematology/Oncology and Ambulatory Infusion Center NMCSD

2012- Staff Physician, Department of Hematology/Oncology, NMC San Diego

2001- Responsible investigator (local principle investigator) CALGB/Alliance Clinical Trials

2007- Oncology Advisory Group, Clinical Liaison Physician NMC San Diego

2016-2017 Congressionally mandated metastatic cancer task force

2017- Murtha Cancer Center MTF Cancer Steering Committee

2013 Master Teacher of the Year, American College of Physicians U. S. Navy Chapter

2015 Master Clinician, Naval Medical Center, San Diego

Representative Bibliography

Gable PS, Le DT, McGehee W, and Rapaport SI. A Protac-Based Screening Test for Activated Protein C-Resistant Factor Va and Other Defects of the Protein C Anticoagulant Pathway. Blood Coagulation and Fibrinolysis 1997;8:1-9

Gable PS, Le DT, and Rapaport SI. The Purified Protein C Activator from the Venom of Agkistrodon Contortrix Contortrix (Protac) Can Activate Factor V and Factor VIII. Thrombosis Research 1997;86:79-84

Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable PS, Torti FM, Kaplan E, and Vogelsgang NJ, Antiandrogen Withdrawal Alone or in Combination With Ketoconazole in Androgen-Independent Prostate Cancer Patients: A Phase III Trial (CALGB 9583) J Clin Oncol 2004;22 1025-1033

Miller HJ, Hu J, Valentine JK, Gable PS. Efficacy and tolerability of intravenous ferric gluconate in the treatment of iron deficiency anemia in patients without kidney disease. Arch Intern Med. 2007 Jun 25;167(12):1327-8.

Belani CP, Ramalingam S, Perry MC, LaRocca RV, Rinaldi D, Gable PS, Tester WJ. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer J Clin Oncol. 2008 Jan 20;26(3):468-73.

Ramalingam S, Perry MC, La Rocca RV, Rinaldi D, Gable PS, Tester WJ, Belani CP. Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer. Cancer. 2008 Aug 1;113(3):542-6

. Shiv E, Shank J, Richard J, Lutgendorf M, Oseni S, and Gable P Treatment of Recurrent Metastatic Breast Cancer in Pregnancy: A Case Report and Literature Review Annals of Clinical Case Reports 2017;2:1432